This notice does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedure "open procedure" (section IV.1.1.) Used in the present announcement text is due to the requirements of the announcement form.This, as well as the use of the medium "TED", does not entail any submission to public procurement regulations, the validity of which by law or Regulation is not mandatory. It is a framework contract with accession option, which refers to various active ingredients.

The subject of the agreement are medicaments containing the active ingredient glatiramer acetate in the active strength 20 mg / ml.

The subject of the agreement is medicaments containing the active ingredient glatiramer acetate in the dosage form FER at an active strength of 40 mg / ml.

The subject of the agreement is medicaments containing the active substance glatiramer acetate in the dosage form PEN at an active strength of 40 mg / ml.